CYP11A1 and neoplasm: The genetic deletion of Cyp11a1 by CRISPR/Cas9 mutagenesis in tumor cells or pharmacological inhibition of Cyp11a1 using aminoglutethimide protected animals from skeletal lesion formation and tumor-induced osteolysis in vivo [108].